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PrevalenceBackground: Earlier studies have documented an association between cytomegalovirus and cognitive
impairment, but results have been inconsistent. Few studies have investigated the association of cytome-
galovirus and Epstein-Barr virus with cognitive decline longitudinally. Our aim was to examine whether
cytomegalovirus and Epstein-Barr virus are associated with cognitive decline in adults.
Method: The study sample is from the Finnish Health 2000 Survey (BRIF8901, n = 7112), which is repre-
sentative of the Finnish adult population. The sample was followed up after 11 years in the Health 2011
Survey. In addition, persons with dementia were identified from healthcare registers.
Results: In the Finnish population aged 30 and over, the seroprevalence of cytomegalovirus was esti-
mated to be 84% and the seroprevalence of Epstein-Barr virus 98%. Seropositivity of the viruses and anti-
body levels were mostly not associated with cognitive performance. In the middle-aged adult group,
cytomegalovirus serointensity was associated with impaired performance in verbal learning. However,
the association disappeared when corrected for multiple testing. No interactions between infection
and time or between the two infections were significant when corrected for multiple testing.
Seropositivity did not predict dementia diagnosis.
Conclusions: The results suggest that adult levels of antibodies to cytomegalovirus and Epstein-Barr virus
may not be associated with a significant decline in cognitive function or with dementia at population
level.
 2018 Published by Elsevier Inc.1. Introduction
Human cytomegalovirus (CMV, also known as human
herpesvirus-5, HHV-5) and Epstein-Barr virus (EBV) are among
the most common viruses in humans. Both viruses are members
of the herpesvirus family and form a lifelong latent infection.
CMV and EBV spread mostly through bodily fluids, such as saliva.
Primary infections, as well as subsequent virus reactivations, are
often asymptomatic or cause only mild symptoms, and therefore
most people do not know that they have been infected. However,
primary infection or reactivation of the viruses can be potentiallylife-threatening to immunocompromised persons (Emery, 2001;
Hodson et al., 2005). In addition, primary infection of CMV during
pregnancy may cause cognitive impairment, hearing loss or visual
impairment to the unborn baby (Dollard et al., 2007). In Finland,
the seroprevalence of CMV was 56% in pregnant women in
South-Western Finland (Alanen et al., 2005), and in another study
the seroprevalence in pregnant women was 76% in a low
socioeconomic area and 61% in a high socioeconomic area of
Helsinki (Mustakangas et al., 2000). The seroprevalence of EBV
has been estimated to be over 90% (Cohen, 2000; Puhakka et al.,
2016). Infections are slightly more prevalent in women and in
persons with low socioeconomic status (Cannon et al., 2010;
Dowd et al., 2013).
Two longitudinal studies with approximately 1000 elderly par-
ticipants found an association between CMV and cognitive decline.
Table 1
Assessed cognitive variables in two age groups in the baseline and in the 11 year
follow-up.
Middle-aged adults Elderly
Cognitive variables Baseline Follow-up Baseline Follow-up
Verbal fluency    
Verbal learning    
Verbal short delay recall    
Simple movement time  
Simple reaction time  
Choice movement time  
Choice reaction time  
Abbreviated Mini-Mental
State Examination
(MMSE)
 
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and cognitive decline and risk of Alzheimer’s disease (Barnes
et al., 2015). Another study detected an association between
CMV immunoglobulin G (IgG) antibody level (serointensity) and
cognitive decline (Aiello et al., 2006). Gow et al. concluded that
CMV infection per se may not associate with cognitive ability when
controlling for background factors associated with the risk of CMV
infection, but having a high level of CMV antibodies associated
with a lower level of cognitive ability (Gow et al., 2013). In con-
trast, Tarter et al. did not find an association between CMV
seropositivity and cognitive impairment in a group of 5000 persons
over 60 years of age (Tarter et al., 2014).
In non-elderly adults, the association between CMV and cogni-
tive functioning has been studied in few cross-sectional studies
with a large sample size. Tarter et al. with almost 5000 middle-
aged persons, detected an association between CMV seropositivity
and cognitive impairment in two out of four cognitive variables
(Tarter et al., 2014). Dickerson et al. reported an association
between high CMV antibody levels and cognitive functioning in
512 individuals (Dickerson et al., 2014).
The effect of CMV infection on cognitive functioning is expected
to be small (Gow et al., 2013; Tarter et al., 2014) and therefore
addressing the question requires a large sample size. Previously
only a few studies have had adequate sample sizes for investigat-
ing the association between CMV and cognitive functioning
(Aiello et al., 2006; Barnes et al., 2015; Tarter et al., 2014). In addi-
tion, because the risk for CMV infection is associated with many
background variables that are also associated with cognitive func-
tioning, the detected association between CMV infection and cog-
nitive functioning could result from not being able to perfectly
control for background factors (i.e. residual confounding) (Gow
et al., 2013). This issue can be solved by using longitudinal data.
Although some longitudinal studies have been published in the
elderly (Aiello et al., 2006; Barnes et al., 2015), as far as we know,
no longitudinal studies on the effects of CMV infection on cognitive
functioning in a non-elderly adult population have been published.
EBV has been less studied than CMV in terms of association
with cognitive functioning. Dickerson et al. studied the association
between EBV and cognition in two studies: 521 non-elderly per-
sons and 229 persons with schizophrenia, and did not detect any
association (Dickerson et al., 2014, 2003). Also in a study with
1000 adolescents, EBV was not associated with cognitive perfor-
mance (Jonker et al., 2014). However, a meta-analysis with only
three small samples found an association between EBV and Alzhei-
mer’s disease (Steel and Eslick, 2015).
The purpose of the present study was to examine whether CMV
and EBV seropositivity and antibody levels are associated with cog-
nitive decline in adults and the elderly and with dementia diagno-
sis using a large, representative population sample.
2. Methods
2.1. Participants
This study is based on the Finnish Health 2000 Survey
(BRIF8901), which is a representative, two-stage stratified cluster
sample of the Finnish population (Aromaa and Koskinen, 2004).
The sample comprised 8028 persons aged 30 years or over living
in mainland Finland. Finland was divided into 20 strata based on
the five university hospital regions and the 15 largest cities in Fin-
land. From each university hospital region, 16 healthcare districts,
including the largest cities, were chosen as clusters. The ultimate
sampling units were persons who were selected by systematic ran-
dom sampling from the healthcare districts. People who were 80
years or older were oversampled using double inclusion probabil-
ity. The study protocol was approved by the Ethics Committee ofthe National Public Health Institute and the Hospital District of
Helsinki and Uusimaa (HUS) (Heistaro, 2008). Written informed
consent was obtained.
Of the total sample, 7112 (88.6%) participated in the health
interview and/or health examination. Data were collected between
September 2000 and June 2001, including a home interview and a
health examination at the local health centre, or for non-
respondents, a condensed interview and health examination per-
formed at home. We excluded persons whose native language
was other than Finnish, or was unknown (n = 558), from the anal-
yses of cognitive performance. After the exclusion, the study group
comprised 6554 persons.
The Health 2000 sample was followed up in 2011 with the
Health 2011 Survey. All persons from the Health 2000 sample
who were alive, living in Finland and had not refused to participate
in any future studies were invited (n = 5733: 5309 persons whose
native language was Finnish), and 4620 participated in the Health
2011 Survey (Markkula et al., 2016).
2.2. Cognitive assessment
The cognitive variables of the present study can be seen in
Table 1. Two tests from the CERAD battery (Moms et al., 1989;
Pulliainen et al., 1999) were performed by all participants. For
the assessment of verbal fluency, participants were requested to
name as many animals as they could within one minute. The num-
ber of correct words was recorded.
In the assessment of verbal learning and memory, the partic-
ipants were shown 10 words one at a time, and were asked to read
the words aloud andmemorize them. The total number of correctly
recalled words was recorded. The words were shown in total three
times, each time in a different order. In Health 2000, if the person
remembered all the words they were not shown again, and the
unshown words were scored as if the person had remembered
them. In this study, we used the total number of immediately
recalled words after each of the showings as a measure of verbal
learning. Short delayed recall after five minutes was categorized
for persons who remembered at least 90%, at least 75% (slightly
impaired) and <75% (impaired) (Hänninen et al., 2013) of the num-
ber of words from the recall in the third showing.
Simple and choice reaction and movement time was recorded
by Good Response (Metitur oy, Jyväskylä) (Era et al., 1986). The
task was to move the index finger when a light lit up from the
waiting switch to the switch that turned the light off as fast as pos-
sible. In the simple task, the light lit up in the same place at ran-
dom intervals. In the choice task, the light lit up in different
places in the testing panel. The tasks were repeated 12 times.
The response was accepted if the response was given within pro-
grammed time limits and was within two standard deviations from
the mean of the subject. Mean simple reaction and movement
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used in the present study. The task was performed only in the
baseline assessment.
As a rough estimate for general cognitive functioning an
abbreviated version of the Mini-Mental State Examination (MMSE),
usually used to assess cognitive decline and screen for dementia
(Folstein et al., 1975), was administered during the home inter-
views for persons who were at least 55 years of age. The subtests
included were the assessment of orientation to time (asking for
the day, month and year), immediate repeating and delayed recall
of three-words, repetition of a phrase, an attention and calculation
task of counting down from one hundred by sevens (serial 7s) and
copying of a drawing (two intersecting pentagons).
2.3. Dementia diagnosis
Persons with dementia in the elderly sample (n = 3065) were
identified from four registers. From the Hospital Discharge Register
and Causes of Death Register we identified persons with the fol-
lowing diagnosis codes: F00, F01, F02, F03, G30 (ICD-10), 3310,
4378A (ICD-9) and 290 (ICD-8/9). Persons who had purchased pre-
scribed, reimbursed medication, or who were entitled to special
reimbursement on the basis of Alzheimer’s disease or Parkinson’s
disease diagnosis, were identified from the Prescription Register
(ATC class N06D) and Special Reimbursement Register (code 307
by the Social Insurance Institution). Of the elderly, 606 persons
had received a dementia diagnosis during the 13-year follow-up
by the end of 2013.
2.4. CMV and EBV IgG level measurement
Plasma samples were available from 6250 (88%) participants.
CMV and EBV IgG levels were analysed by solid-phase immunoas-
say using commercially available assay kits (IBL America) as
described by Dickerson et al. (2003). In the present study, we used
seropositivity of the infection, which was rated positive if the opti-
mal density value was above or at the infection point in the sample
distribution, as well as continuous variables of serointensity.
2.5. Statistical analysis
The sampling design was accounted for in the analyses. In addi-
tion, post-stratification weights were used to correct for unit non-
response and oversampling of persons over 80 years of age. Miss-
ing values for those who had participated in any part of the study
in 2000 (n = 7112) were imputed by chained equations and ran-
dom forest imputation using mice package (Van Buuren and
Groothuis-Oudshoorn, 2011) in R version 3.2.2 (R Core Team,
2015). Missing values in 2011 were imputed only for those who
were alive and living in Finland.
Age and sex standardized seroprevalence in sociodemographic
groups using imputed values was calculated as predictive margins
using ‘‘mimrgns” (Graubard and Korn, 1999) in Intercooled Stata
11.0 (StataCorp, 2009). R was used for the regression analyses
(Lumley, 2004). The analyses of cognitive performance were per-
formed with persons whose native language was Finnish and sep-
arately for two age groups: younger (age <55 at baseline) and older
(age 55 at baseline). The association between seropositivity to
the viruses and cognitive performance was first analysed. Next,
the analyses were repeated with the serointensity of CMV and
EBV antibodies. The analyses were controlled for age, sex, years
of education, marital status (married or cohabiting vs. others)
and urbanicity. To analyse cognitive decline during 11-year
follow-up, two-way interactions between time and infection and
three-way interaction between the two infections and time were
analysed. To ensure that non-linear effects were not missed, wefurther divided those seropositive for the virus into quintiles of
serointensity (CMV ranges were approximately <3.7, 3.7–4.4,
4.5–5.3, 5.3–6.2, >6.2 and EBV serointensity ranges <0.9, 0.9–1.2,
1.2–1.5, 1.5–2 and 2) and repeated the analyses of cognitive per-
formance with those variables.
The association of the viruses with dementia diagnosis was
studied using Cox regression. The analyses were done for persons
at least 55 years of age and controlled for age, sex, years of educa-
tion, marital status, native language and urbanicity.
P-values of <.05 were considered statistically significant. Cor-
rection for multiple comparisons was performed with false discov-
ery rate using Benjamini–Hochberg procedure (Benjamini and
Hochberg, 1995).3. Results
3.1. Analysis of missingness
There were no missing values for age, sex, urbanicity or region
of residence. Education was missing for 3% of the participants, mar-
ital status for 0.3% and native language for 0.4%.
Plasma sample for the analysis of the infections was available
for 5783 participants whose native language was Finnish (88%).
At baseline, at least a part of cognitive data was available for
6144 (94%) persons, and 5527 (84%) persons did not have any
missing values in verbal fluency, verbal learning or reaction time
tasks. In total, 4324 persons (66% of the persons at baseline and
81% of the persons who were alive, had not moved abroad and
had not refused further contact) persons participated in the
follow-up. Missing information in the variables was predicted by:
older age, being a man, having lower education and not being mar-
ried or cohabiting (Supplementary Table 1). Good performance in
verbal fluency was associated with higher probability of perform-
ing MMSE and choice reaction time tests. Multiple imputation
was used in order to take into account missingness. Register-
based follow-up of dementia diagnoses covered all the partici-
pants, and hence there was no missingness.3.2. Prevalence of CMV and EBV
The seroprevalence of CMV was estimated to be 84.0% (95% CI
83.0–84.9). The seroprevalence of EBV was 98.1% (95% CI 97.7–
98.4). Sociodemographic characteristics and seroprevalence of
CMV and EBV in sociodemographic groups are shown in Table 2.3.3. Association between the viruses and cognitive functioning
Seropositivity or serointensity of CMV or EBV were mostly not
associated with cognitive decline (studied with infection  time
interaction) or cross-sectional cognitive performance in the two
age groups after adjusting for age, sex, years of education, marital
status (married or cohabiting vs. others) and urbanicity. In the
middle-aged adult group, CMV serointensity was associated with
impaired performance in verbal learning (B = 0.12, p = .04) in
fourteen models done before correction for multiple comparisons.
In the elderly group, CMV serointensity  time interaction was
associated with verbal fluency (B = 0.38, p = .04) and EBV serointen
sity  time interaction (B = 0.63, p = .05) and CMV serointensity 
EBV serointensity  time interaction (B = 0.13, p = .04) with ver-
bal learning in sixteen models done before correction for multiple
comparisons. However, the associations were non-significant
when corrected for multiple testing. We additionally tested inter-
actions with sex and education years, but they were non-
significant and were removed from the analyses.
Table 2
Sociodemographic characteristics of the participants and CMV and EBV seroprevalence in sociodemographic groups as predictive margins adjusting for age and sex.
Proportion (%) or mean 95% CI CMV (%) 95% CI (%) EBV (%) 95% CI (%)
Age 53.0 52.6–53.4
30–40 24.0 22.9–25.0 73.2 70.9–75.6 96.9 96.1–97.8
41–54 35.2 34.1–36.3 83.5 81.9–85.1 98.4 97.9–98.9
55–70 25.4 24.4–26.5 90.1 88.7–91.5 97.9 97.2–98.6
71> 15.3 14.4–16.2 91.9 89.9–94.0 99.3 98.1–99.8
Sex
Women 52.5 51.3–53.7 86.3 85.0–87.7 98.4 98.0–98.8
Men 47.5 46.3–48.7 81.5 80.3–82.8 97.7 97.1–98.3
Education years 11.1 10.9–11.2
Basic 40.4 38.8–42.0 85.2 83.4–87.0 98.2 97.6–98.8
Secondary 26.5 25.3–27.6 85.8 84.2–87.5 98.5 98.0–99.1
High 33.1 31.7–34.4 81.5 80.0–83.1 97.6 96.9–98.3
Marital status
Married or cohabiting 67.8 66.6–68.9 84.8 83.7–85.8 98.3 97.9–98.7
Single, separated or widowed 32.2 31.1–33.4 81.9 80.1–83.8 97.4 96.7–98.2
Native language
Finnish 92.9 89.9–95.9 84.2 83.2–85.2 98.1 97.7–98.5
Swedish 5.3 2.5–8.2 77.7 74.1–81.2 97.7 95.7–99.7
Other 1.8 1.0–2.6 89.3 83.3–95.2 98.9 96.8–100
Urbanicity
Urban 61.4 55.1–67.6 83.3 82.2–84.5 98.2 97.8–98.6
Semi-urban 14.4 8.4–20.4 87.0 85.0–88.9 98.2 97.3–99.0
Rural 24.2 18.0–30.5 83.8 81.7–85.9 97.7 96.7–98.7
Region of residence
North 13.4 13.2–13.6 87.7 85.8–89.6 98.4 97.7–99.1
East 17.2 16.9–17.5 85.1 82.9–87.3 97.6 96.6–98.6
West 23.0 22.5–23.6 85.1 82.9–87.3 98.0 97.2–98.8
Southwest 13.5 13.2–13.8 82.8 80.4–85.2 98.8 98.1–99.4
South 32.9 32.3–33.5 81.6 79.8–83.4 97.9 97.1–98.7
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tensity were associated with cognitive performance in those
seropositive for the virus (Fig. 1). EBV quintiles were not associated
with cognitive performance. In the middle-aged adults, the third
quintile of CMV performed worse than the lowest quintile in verbal
fluency (B = 0.91, p = .03) and in verbal learning (B = 0.58,
p = .007). In addition, CMV quintile  time interaction was signifi-
cant in verbal learning (B = 0.68, p = .02) between the lowest and
the third quintiles, signifying that persons in the third serointen-
sity quintile improved their performance more than persons in
the lowest quintile. Also, the second quintile (B = 0.006, p = .045)
and the third quintile (B = 0.007, p = .01) had worse performance
than the lowest quintile in movement time in the simple task. In
the elderly, the highest quintile of CMV performed worse than
the lowest quintile in movement time in the choice task
(B = 0.03, p = .02). None of the significant results passed the test
for multiple comparisons when corrected for fourteen or sixteen
models done in the age groups.
Of the elderly group, 17% received a dementia diagnosis. When
using age- and sex-adjusted predictive margins, 17% (95% CI
15.8%–18.5%) of persons with and 18% (95% CI 12.5%–23.6%) of per-
sons without CMV received a dementia diagnosis. With similar
estimation, 17% (95% CI 16.1%–18.5%) of the persons with EBV
and 10.3% (95% CI 0.0%–21.1%) of the persons without EBV received
a dementia diagnosis. Seropositivity of CMV (HR = 1.32, 95% CI
0.12–15.0) or EBV (HR = 2.24, 95% CI 0.36–16.4), or the interaction
between the viruses (HR = 0.64, 95% CI 0.05–7.65), were not asso-
ciated with a dementia diagnosis. Because of wide confidence
intervals, the analysis was confirmed without interaction and the
results remained similar (CMV: HR = 0.85, 95% CI 0.57–1.27; EBV:
HR = 1.74, 95% CI 0.51–5.92). The associations were also
non-significant using serointensity (CMV: HR = 0.99, 95% CI
0.88–1.11; EBV: 1.10, 95% CI 0.83–1.47; interaction: HR = 0.99,
95% CI 0.93–1.06).4. Discussion
The results of this study suggest that CMV or EBV may not
have a significant effect on cognitive functioning or dementia risk
in the general population. The two viruses were not associated
with cognitive decline over time in middle-aged adults nor the
elderly. In the adults, CMV was associated with lower perfor-
mance in one cognitive variable out of fourteen models done,
but the significant association disappeared when corrected for
multiple testing.
In the Finnish population aged 30 and over, the seroprevalence
of CMV was estimated to be 84%. The prevalence of CMV in people
aged 30–40 was 73%. When considering the fact that the sero-
prevalence rises with age, our results are close to earlier reported
seroprevalences of 56% and 71% in pregnant women mostly
between 20 and 40 years (Alanen et al., 2005; Mustakangas et al.,
2000). The 98% seroprevalence of the EBV was consistent with
results of the earlier study by Puhakka et al. (2016).
The lack of association between CMV and cognitive decline or
cognitive performance was unexpected. The results of previous
studies have been mixed, but most studies noticed at least some
statistically significant association between cognitive functioning
and CMV (Aiello et al., 2006; Barnes et al., 2015; Dickerson et al.,
2014; Gow et al., 2013; Tarter et al., 2014). The largest study to
date, with over 4000 children, 5000 middle-aged adults and 5000
seniors, noticed an association between CMV and cognitive func-
tioning in two out of four variables only in the middle-aged adults,
not in the other groups (Tarter et al., 2014). No association
between CMV and dementia diagnosis was in contrast with results
from Barnes et al. (2015), but in line with other studies with smal-
ler sample sizes (Steel and Eslick, 2015). The results of the present
study, together with earlier studies, suggest that if an association
between CMV infection and cognitive decline at population level
exists, the effect size must be minimal.
Fig. 1. Performance in verbal learning task at baseline of persons who are seronegative for CMV or EBV and persons who are seropositive grouped into quintiles of
serointensity in the whole sample. Performance (mean and 95% confidence intervals) was calculated as predictive margins adjusting for age, sex, years of education, marital
status and urbanicity.
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of no associations with cognitive functioning (Dickerson et al.,
2014, 2003; Jonker et al., 2014). We replicated the result with a lar-
ger sample size than earlier and with information on change over
11 years. The EBV was not associated with emergent dementia
either. The result was in contrast to the results of a meta-
analysis of three small samples, which concluded that EBV would
associate with the risk of Alzheimer’s disease. However, the confi-
dence interval in the present study was wide because almost
everyone had EBV, therefore making the interpretation of the
results difficult. The analyses with the serointensity of EBV sup-
ported the conclusion that EBV would not associate with dementia.
The strengths of the study include a large sample that is repre-
sentative of the Finnish adult population and a long follow-up
time. The participation rate was excellent (89%) at baseline andlower but still good at the follow-up (71% of the whole sample).
Due to information on non-participants, it was possible to correct
for non-response. A weakness of the study is that we did not have
a new assessment of the viral antibodies at the follow-up, therefore
we were not able to study the effects of seroconversion. In addi-
tion, the cognitive test battery used in the present study was short.
We excluded persons whose native language was other than Fin-
nish from the analyses of cognitive performance thus possibly lim-
iting the generalizability of the results to people with native
language other than Finnish.
5. Conclusions
Evidence has been accumulating recently that inflammation
could be a cause of neurodegeneration in the elderly (Ransohoff,
M. Torniainen-Holm et al. / Brain, Behavior, and Immunity 69 (2018) 480–485 4852016). However, the results of the present study suggest that CMV
or EBV may not be causative agents of neurodegeneration at pop-
ulation level. Both CMV and EBV are very common infections in the
general population and, for most of the people, the viruses cause
such mild symptoms that people are unaware of the infection. Pos-
sibly, CMV and EBV are associated with cognitive functioning in a
subpopulation, such as in persons who are more vulnerable to the
effects of virus infection due to other diseases or genetic suscepti-
bility. Because our sample was highly representative of the general
population in Finland and because of the large sample size, the
result of no association between the two viruses and cognitive
decline at population level is plausible.
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